Home＞REGULATORY
Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder(Jun.13.2016)
The Pharmaceuticals and Medical Devices Agency (PMDA) said on June 10 that it is reviewing the risks of hypertension and cerebrovascular disorder for hepatitis C drugs Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir), a move that is likely to result ...
(LOG IN FOR FULL STORY)
-
- Govt OKs Basic Policy for FY2018 Budget Requests Jul.21
-
Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS
Jul.20
- MHLW Panel to Discuss Zetia + Lipitor Combination Product on Aug. 1 Jul.20
- Shiozaki Says MHLW to Uphold 3-Year 1.5 Trillion Yen Cap in Social Security Cost Rise, CEFP Panelists Call for Further Curtailment Jul.19
- Azithromycin under PMDA Risk Review for Acute Generalized Exanthematous Pustulosis Jul.19
- Govt OKs Basic Policy for FY2018 Budget Requests(Jul.21)
- AZ Japan Facing Civil Lawsuit over Demotions, Pay Cuts(Jul.21)
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe(Jul.21)
- Hypertension Treatment Guidelines for Elderly Finalized with Recommendations on Dosage Reduction, Discontinuation(Jul.21)
- Putting on Your Pants(Jul.21)
